These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24188585)

  • 1. Which antibiotic for resistant Gram-positives, and why?
    Bradley JS
    J Infect; 2014 Jan; 68 Suppl 1():S63-75. PubMed ID: 24188585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving linezolid use decreases the incidence of resistance among Gram-positive microorganisms.
    Ramírez E; Gómez-Gil R; Borobia AM; Moreno F; Zegarra C; Muñoz R; Reutero Z; de Montreuil C; González D; Hernández S; Herrero A; Gutiérrez A; Frías J
    Int J Antimicrob Agents; 2013 Feb; 41(2):174-8. PubMed ID: 23276501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and prospective treatments for multidrug-resistant gram-positive infections.
    Rybak JM; Barber KE; Rybak MJ
    Expert Opin Pharmacother; 2013 Oct; 14(14):1919-32. PubMed ID: 23876168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis.
    Pai AB; Pai MP
    Adv Chronic Kidney Dis; 2006 Jul; 13(3):259-70. PubMed ID: 16815231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer developments in the treatment of Gram-positive infections.
    Koomanachai P; Crandon JL; Nicolau DP
    Expert Opin Pharmacother; 2009 Dec; 10(17):2829-43. PubMed ID: 19929705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin: understanding its past and preserving its future.
    Levine DP
    South Med J; 2008 Mar; 101(3):284-91. PubMed ID: 18364659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections caused by Gram-positive bacteria: a review of the global challenge.
    Woodford N; Livermore DM
    J Infect; 2009 Sep; 59 Suppl 1():S4-16. PubMed ID: 19766888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
    Thakkar RK; Monaghan SF; Adams CA; Stephen A; Connolly MD; Gregg S; Cioffi WG; Heffernan DS
    J Surg Res; 2013 May; 181(2):323-8. PubMed ID: 22906560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with daptomycin: bacteraemia and endocarditis.
    Levine DP
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches for empiric therapy in Gram-positive sepsis.
    Bassetti M; Ginocchio F; Giacobbe DR
    Minerva Anestesiol; 2011 Aug; 77(8):821-7. PubMed ID: 21730930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria].
    Candel González FJ
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():10-6. PubMed ID: 22541970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of gram-positive coccal bacteremia and hemodialysis.
    Fitzgibbons LN; Puls DL; Mackay K; Forrest GN
    Am J Kidney Dis; 2011 Apr; 57(4):624-40. PubMed ID: 21333430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of treatments used in infections caused by gram-positive multiresistant cocci in critically ill patients admitted to the ICU].
    Álvarez-Lerma F; Palomar Martínez M; Olaechea Astigarraga P; Insausti Ordeñana J; López Pueyo MJ; Gracia Arnillas MP; Gimeno Costa R; Seijas Betolaza I
    Rev Esp Quimioter; 2012 Mar; 25(1):65-73. PubMed ID: 22488544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cSSTIs: the role of daptomycin.
    Garau J
    Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving resistance among Gram-positive pathogens.
    Munita JM; Bayer AS; Arias CA
    Clin Infect Dis; 2015 Sep; 61 Suppl 2(Suppl 2):S48-57. PubMed ID: 26316558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.